Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Program: Scientific Session
General Topic: Clinical

Gazing into the Crystal Ball: Gout and Cardiometabolic Comorbidity Management

Monday, October 27, 2025
8:00 AM – 9:30 AM Central Time

    Moderator(s)

  • MT

    Michael Toprover, MD

    New York University Langone Health
    New York, NY, United States

    Disclosure(s): Amgen: Consultant (Terminated, October 20, 2023); Scilex Holding: Advisor or Review Panel Member (Terminated, November 15, 2024)

  • Puja Khanna, MD, MPH (she/her/hers)

    University of Michigan
    Ann Arbor, Michigan, United States

    Disclosure(s): Arthrosi: Grant/Research Support (Ongoing); Horizon/Amgen: Grant/Research Support (Ongoing); Olatec: Grant/Research Support (Ongoing); SOBI: Consultant (Ongoing)

    • Session Coordinator(s)

  • MT

    Michael Toprover, MD

    New York University Langone Health
    New York, NY, United States

    Disclosure(s): Amgen: Consultant (Terminated, October 20, 2023); Scilex Holding: Advisor or Review Panel Member (Terminated, November 15, 2024)

  • Puja Khanna, MD, MPH (she/her/hers)

    University of Michigan
    Ann Arbor, Michigan, United States

    Disclosure(s): Arthrosi: Grant/Research Support (Ongoing); Horizon/Amgen: Grant/Research Support (Ongoing); Olatec: Grant/Research Support (Ongoing); SOBI: Consultant (Ongoing)

  • NS

    Naomi Schlesinger, MD

    University of Utah
    Salt Lake City, Utah, United States

    Disclosure(s): arthrosi: Advisor or Review Panel Member (Ongoing); avalo: Advisor or Review Panel Member (Ongoing); horizon: Advisor or Review Panel Member (Ongoing); olatec: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); protalix: Advisor or Review Panel Member (Ongoing); scilex: Advisor or Review Panel Member (Ongoing); shanton: Advisor or Review Panel Member (Ongoing); sobi: Advisor or Review Panel Member (Ongoing)

Gout is a common cause of inflammatory arthritis and is often undertreated due to its strong association with cardiovascular, metabolic, and renal comorbidities. Recent updates on the epidemiology of gout, including the interplay between comorbidities and urate levels that prompt frequent gout flares, as well as the risk of various causes of cardiovascular morbidities driving mortality in gout patients, demonstrate the importance of recognizing them early and educating patients on their risks life-threatening conditions, such as myocardial infarction and stroke. Existing and emerging therapeutics in gout may potentially treat gout and coexisting comorbidities. This session will focus on: 1. Updates in the epidemiology of gout, including incidence of gout in patients with various metabolic syndromes, 2. Discuss the increased prevalence of adverse cardiometabolic outcomes among gout patients, and 3. Review therapies that can treat both gout and its cardiometabolic risk factors.

Learning Objectives:

  • Construct a framework to identify comorbid conditions that may predispose the patient to develop gout
  • Estimate the cardiovascular risks early in patients with gout
  • Evaluate the treatment options available to treat gout and its comorbidities

Presentations:

  • 8:00 AM – 8:30 AM Central Time
    The Metabolic Syndrome and Development of Gout

    Speaker: Natalie McCormick, PhD – Massachusetts General Hospital

  • 8:30 AM – 9:00 AM Central Time
    Cardiovascular Morbidity and Mortality in Gout Patients

    Speaker: Jasvinder Singh, MD, MPH – Baylor College of Medicine

  • 9:00 AM – 9:30 AM Central Time
    Treatments of Gout and its Metabolic Risk Factors

    Speaker: Naomi Schlesinger, MD – University of Utah